In-licensing of European Rights to Rapinyl™ and Pre-close period Trading Update - 21/12/2005
Click to read more
Tostrex Launch - 29/9/2005
ProStrakan Group plc announces today that its new testosterone replacement therapy, Tostrex® 2% gel, for use in hypogonadal men has been launched onto the Swedish market.Click to read more
First medicine licensed specifically for the relief of chronic anal fissure pain launched in UK - 27/5/2005
Click to read more
Announcement of indicative value range of £160 million to £190 million - 26/5/2005
Click to read more
Acquisition of APS Pharma GmbH expands ProStrakan's European sales & marketing operation - 3/5/2005
Click to read more
ProStrakan appoints former AstaZeneca VP of Global Licensing as Non-Executive Director - 24/4/2005
Click to read more